Proposing Melasma Severity Index: A New, More Practical, Office-based Scoring System for Assessing the Severity of Melasma

Overview

Journal Indian J Dermatol

Specialty Dermatology

Date 2016 Mar 9

PMID 26955093

Citations 3

Authors

Imran Majid

Inaamul Haq

Saher Imran

Abid Keen

Khalid Aziz

Tasleem Arif

Affiliations

Soon will be listed here.

Abstract

Background: Melasma Area and Severity Index (MASI), the scoring system in melasma, needs to be refined.

Aims And Objectives: To propose a more practical scoring system, named as Melasma Severity Index (MSI), for assessing the disease severity and treatment response in melasma.

Materials And Methods: Four dermatologists were trained to calculate MASI and also the proposed MSI scores. For MSI, the formula used was 0.4 (a × p(2)) l + 0.4 (a × p(2)) r + 0.2 (a × p(2)) n where "a" stands for area, "p" for pigmentation, "l" for left face, "r" for right face, and "n" for nose. On a single day, 30 enrolled patients were randomly examined by each trained dermatologist and their MASI and MSI scores were calculated. Next, each rater re-examined every 6(th) patient for repeat MASI and MSI scoring to assess intra- and inter-rater reliability of MASI and MSI scores. Validity was assessed by comparing the individual scores of each rater with objective data from mexameter and ImageJ software.

Results: Inter-rater reliability, as assessed by intraclass correlation coefficient, was significantly higher for MSI (0.955) as compared to MASI (0.816). Correlation of scores with objective data by Spearman's correlation revealed higher rho values for MSI than for MASI for all raters.

Limitations: Sample population belonged to a single ethnic group.

Conclusions: MSI is simpler and more practical scoring system for melasma.

Citing Articles

Latin American consensus on the treatment of melasma.

Ocampo-Candiani J, Alas-Carbajal R, Bonifaz-Araujo J, Marin-Castro H, Valenzuela-Ahumada F, Veliz-Barandiaran J Int J Dermatol. 2024; 64(3):499-512.

PMID: 39415312 PMC: 11840225. DOI: 10.1111/ijd.17522.

Autolougous platelet concentrates in esthetic medicine.

Davies C, Miron R Periodontol 2000. 2024; 97(1):363-419.

PMID: 39086171 PMC: 11808453. DOI: 10.1111/prd.12582.

Clinically observed geometric melasma area patterns (GMAPs) and its significance in area assessment: a cross-sectional study of 242 cases.

Anisha Y, Prathyusha P, Ashwini S, Kanthraj G Arch Dermatol Res. 2024; 316(6):298.

PMID: 38819672 DOI: 10.1007/s00403-024-03093-y.

Intradermal Tranexamic Acid Injection for the Treatment of Melasma: A Pilot Study with 48-week Follow-up.

Lueangarun S, Sirithanabadeekul P, Wongwicharn P, Namboonlue C, Pacharapakornpong S, Juntongjin P J Clin Aesthet Dermatol. 2020; 13(8):36-39.

PMID: 33178380 PMC: 7595366.

Association between heterozygote Val92Met gene polymorphisms with incidence of melasma: a study of Javanese women population in Yogyakarta.

Suryaningsih B, Sadewa A, Wirohadidjojo Y, Soebono H Clin Cosmet Investig Dermatol. 2019; 12:489-495.

PMID: 31308719 PMC: 6614830. DOI: 10.2147/CCID.S206115.

References

Balkrishnan R, McMichael A, Camacho F, Saltzberg F, Housman T, Grummer S . Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003; 149(3):572-7. DOI: 10.1046/j.1365-2133.2003.05419.x. View

Guevara I, Pandya A . Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol. 2003; 42(12):966-72. DOI: 10.1111/j.1365-4632.2003.02017.x. View

Trelles M, Velez M, Gold M . The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol. 2010; 9(4):315-22. View

Grimes P . Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995; 131(12):1453-7. DOI: 10.1001/archderm.131.12.1453. View

Freitag F, Cestari T, Leopoldo L, Paludo P, Boza J . Effect of melasma on quality of life in a sample of women living in southern Brazil. J Eur Acad Dermatol Venereol. 2008; 22(6):655-62. DOI: 10.1111/j.1468-3083.2007.02472.x. View

El-Essawi D, Musial J, Hammad A, Lim H . A survey of skin disease and skin-related issues in Arab Americans. J Am Acad Dermatol. 2007; 56(6):933-8. DOI: 10.1016/j.jaad.2007.01.031. View

Weistenhofer W, Baumeister T, Drexler H, Kutting B . An overview of skin scores used for quantifying hand eczema: a critical update according to the criteria of evidence-based medicine. Br J Dermatol. 2009; 162(2):239-50. DOI: 10.1111/j.1365-2133.2009.09463.x. View

Jeong S, Shin J, Yeo U, Kim W, Kim I . Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg. 2010; 36(6):909-18. DOI: 10.1111/j.1524-4725.2010.01523.x. View

Pandya A, Hynan L, Bhore R, Riley F, Guevara I, Grimes P . Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2010; 64(1):78-83, 83.e1-2. DOI: 10.1016/j.jaad.2009.10.051. View

10.

Taylor S, Torok H, Jones T, Lowe N, Rich P, Tschen E . Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003; 72(1):67-72. View

11.

Ashcroft D, Wan Po A, Williams H, Griffiths C . Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141(2):185-91. DOI: 10.1046/j.1365-2133.1999.02963.x. View

12.

Cestari T, Arellano I, Hexsel D, Ortonne J . Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol. 2009; 23(7):760-72. DOI: 10.1111/j.1468-3083.2009.03251.x. View

13.

FREDRIKSSON T, Pettersson U . Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157(4):238-44. DOI: 10.1159/000250839. View

14.

Griffiths C, Finkel L, Hamilton T, Ellis C, Voorhees J . Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994; 130(6):727-33. View

15.

Chan R, Park K, Lee M, Lee E, Chang S, Leow Y . A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008; 159(3):697-703. DOI: 10.1111/j.1365-2133.2008.08717.x. View